Blar i Bergen Open Research Archive på forfatter "Sekulic, Miroslav"
-
Clear cell renal cell carcinoma is linked to epithelial-to-mesenchymal transition and to fibrosis
Landolt, Lea Zoe; Eikrem, Øystein Solberg; Strauss, Philipp; Scherer, Andreas; Lovett, David H.; Beisland, Christian; Finne, Kenneth; Osman, Tarig Al-Hadi; Ibrahim, Mohammad Madani; Gausdal, Gro; Ahmed, Lavina; Lorens, James; Thiery, Jean Paul; Tan, Tuan Zea; Sekulic, Miroslav; Marti, Hans-Peter (Peer reviewed; Journal article, 2017)Clear cell renal cell carcinoma (ccRCC) represents the most common type of kidney cancer with high mortality in its advanced stages. Our study aim was to explore the correlation between tumor epithelial-to-mesenchymal ... -
Kidney Dysfunction and Pathology in the Setting of Hemophagocytic Lymphohistiocytosis
Sekulic, Miroslav; Batal, Ibrahim; Kudose, Satoru; Santoriello, Dominick; Stokes, M. Barry; Jim, Belinda; Marti, Hans Peter; Eikrem, Øystein Solberg; Radhakrishnan, Jai; D'Agati, Vivette D.; Markowitz, Glen S. (Journal article; Peer reviewed, 2023)Introduction Hemophagocytic lymphohistiocytosis (HLH) is a clinicopathologic syndrome produced by dysregulated activation of the immune system. Acute kidney injury (AKI) and proteinuria have been infrequently described ... -
Network-Based Assessment of Minimal Change Disease Identifies Glomerular Response to IL-7 and IL-12 Pathways Activation as Innovative Treatment Target
Eikrem, Øystein Solberg; Lillefosse, Bjørnar; Delaleu, Nicolas; Strauss, Philipp; Osman, Tarig Al-Hadi; Vikse, Bjørn Egil; Debiec, Hanna; Ronco, Pierre; Sekulic, Miroslav; Koch, Even Evjen; Furriol, Jessica; Leh, Sabine; Marti, Hans Peter (Journal article; Peer reviewed, 2023)Background: Minimal change disease (MCD), a major cause of nephrotic syndrome, is usually treated by corticosteroid administration. MCD unresponsiveness to therapy and recurrences are nonetheless frequently observed, ... -
Systems analyses of the Fabry kidney transcriptome and its response to enzyme replacement therapy identified and cross-validated enzyme replacement therapy-resistant targets amenable to drug repurposing
Delaleu, Nicolas; Marti, Hans Peter; Strauss, Philipp; Sekulic, Miroslav; Osman, Tarig Al-Hadi; Tøndel, Camilla; Skrunes, Rannveig; Leh, Sabine; Svarstad, Einar; Nowak, Albina; Gaspert, Ariana; Rusu, Elena; Kwee, Ivo; Rinaldi, Andrea; Flatberg, Arnar; Eikrem, Øystein Solberg (Journal article; Peer reviewed, 2023)Fabry disease is a rare disorder caused by variations in the alpha-galactosidase gene. To a degree, Fabry disease is manageable via enzyme replacement therapy (ERT). By understanding the molecular basis of Fabry nephropathy ...